Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects

Trevi A. Ramirez, Rugmani Padmanabhan Iyer, Omid Ghasemi, Elizabeth F. Lopez, Daniel B. Levin, Jianhua Zhang, Rogelio Zamilpa, Youn Min Chou, Yu Fang Jin, Merry L Lindsey

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We evaluated whether aliskiren, valsartan, or a combination of both was protective following myocardial infarction (MI) through effects on matrix metalloproteinase (MMP)-9. C57BL/6J wild type (WT, n. = 94) and MMP-9 null (null, n. = 85) mice were divided into 4 groups at 3. h post-MI: saline (S), aliskiren (A; 50. mg/kg/day), valsartan (V; 40. mg/kg/day), or A. +. V and compared to no MI controls at 28. days post-MI. All groups had similar infarct areas, and survival rates were higher in the null mice. The treatments influenced systolic function and hypertrophy index, as well as extracellular matrix (ECM) and inflammatory genes in the remote region, indicating that primary effects were on the viable myocardium. Saline treated WT mice showed increased end systolic and diastolic volumes and hypertrophy index, along with reduced ejection fraction. MMP-9 deletion improved LV function post-MI. Aliskiren attenuated the increase in end systolic volume and hypertrophy index, while valsartan improved end diastolic volumes and aliskiren. +. valsartan improved the hypertrophy index only when MMP-9 was absent. Extracellular matrix and inflammatory gene expression showed distinct patterns among the treatment groups, indicating a divergence in mechanisms of remodeling. This study shows that MMP-9 regulates aliskiren and valsartan effects in mice. These results in mice provide mechanistic insight to help translate these findings to post-MI patients.

Original languageEnglish (US)
Pages (from-to)326-335
Number of pages10
JournalJournal of Molecular and Cellular Cardiology
Volume72
DOIs
StatePublished - Jan 1 2014

Fingerprint

Valsartan
Ventricular Remodeling
Matrix Metalloproteinase 9
Myocardial Infarction
Hypertrophy
Extracellular Matrix
aliskiren
Myocardium
Survival Rate

Keywords

  • Aliskiren
  • Extracellular matrix
  • MMP-9
  • Myocardial infarction
  • Remodeling
  • Valsartan

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects. / Ramirez, Trevi A.; Iyer, Rugmani Padmanabhan; Ghasemi, Omid; Lopez, Elizabeth F.; Levin, Daniel B.; Zhang, Jianhua; Zamilpa, Rogelio; Chou, Youn Min; Jin, Yu Fang; Lindsey, Merry L.

In: Journal of Molecular and Cellular Cardiology, Vol. 72, 01.01.2014, p. 326-335.

Research output: Contribution to journalArticle

Ramirez, Trevi A. ; Iyer, Rugmani Padmanabhan ; Ghasemi, Omid ; Lopez, Elizabeth F. ; Levin, Daniel B. ; Zhang, Jianhua ; Zamilpa, Rogelio ; Chou, Youn Min ; Jin, Yu Fang ; Lindsey, Merry L. / Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects. In: Journal of Molecular and Cellular Cardiology. 2014 ; Vol. 72. pp. 326-335.
@article{fc7ee1a05e334ec680cc396db6eb0553,
title = "Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects",
abstract = "We evaluated whether aliskiren, valsartan, or a combination of both was protective following myocardial infarction (MI) through effects on matrix metalloproteinase (MMP)-9. C57BL/6J wild type (WT, n. = 94) and MMP-9 null (null, n. = 85) mice were divided into 4 groups at 3. h post-MI: saline (S), aliskiren (A; 50. mg/kg/day), valsartan (V; 40. mg/kg/day), or A. +. V and compared to no MI controls at 28. days post-MI. All groups had similar infarct areas, and survival rates were higher in the null mice. The treatments influenced systolic function and hypertrophy index, as well as extracellular matrix (ECM) and inflammatory genes in the remote region, indicating that primary effects were on the viable myocardium. Saline treated WT mice showed increased end systolic and diastolic volumes and hypertrophy index, along with reduced ejection fraction. MMP-9 deletion improved LV function post-MI. Aliskiren attenuated the increase in end systolic volume and hypertrophy index, while valsartan improved end diastolic volumes and aliskiren. +. valsartan improved the hypertrophy index only when MMP-9 was absent. Extracellular matrix and inflammatory gene expression showed distinct patterns among the treatment groups, indicating a divergence in mechanisms of remodeling. This study shows that MMP-9 regulates aliskiren and valsartan effects in mice. These results in mice provide mechanistic insight to help translate these findings to post-MI patients.",
keywords = "Aliskiren, Extracellular matrix, MMP-9, Myocardial infarction, Remodeling, Valsartan",
author = "Ramirez, {Trevi A.} and Iyer, {Rugmani Padmanabhan} and Omid Ghasemi and Lopez, {Elizabeth F.} and Levin, {Daniel B.} and Jianhua Zhang and Rogelio Zamilpa and Chou, {Youn Min} and Jin, {Yu Fang} and Lindsey, {Merry L}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.yjmcc.2014.04.007",
language = "English (US)",
volume = "72",
pages = "326--335",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects

AU - Ramirez, Trevi A.

AU - Iyer, Rugmani Padmanabhan

AU - Ghasemi, Omid

AU - Lopez, Elizabeth F.

AU - Levin, Daniel B.

AU - Zhang, Jianhua

AU - Zamilpa, Rogelio

AU - Chou, Youn Min

AU - Jin, Yu Fang

AU - Lindsey, Merry L

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We evaluated whether aliskiren, valsartan, or a combination of both was protective following myocardial infarction (MI) through effects on matrix metalloproteinase (MMP)-9. C57BL/6J wild type (WT, n. = 94) and MMP-9 null (null, n. = 85) mice were divided into 4 groups at 3. h post-MI: saline (S), aliskiren (A; 50. mg/kg/day), valsartan (V; 40. mg/kg/day), or A. +. V and compared to no MI controls at 28. days post-MI. All groups had similar infarct areas, and survival rates were higher in the null mice. The treatments influenced systolic function and hypertrophy index, as well as extracellular matrix (ECM) and inflammatory genes in the remote region, indicating that primary effects were on the viable myocardium. Saline treated WT mice showed increased end systolic and diastolic volumes and hypertrophy index, along with reduced ejection fraction. MMP-9 deletion improved LV function post-MI. Aliskiren attenuated the increase in end systolic volume and hypertrophy index, while valsartan improved end diastolic volumes and aliskiren. +. valsartan improved the hypertrophy index only when MMP-9 was absent. Extracellular matrix and inflammatory gene expression showed distinct patterns among the treatment groups, indicating a divergence in mechanisms of remodeling. This study shows that MMP-9 regulates aliskiren and valsartan effects in mice. These results in mice provide mechanistic insight to help translate these findings to post-MI patients.

AB - We evaluated whether aliskiren, valsartan, or a combination of both was protective following myocardial infarction (MI) through effects on matrix metalloproteinase (MMP)-9. C57BL/6J wild type (WT, n. = 94) and MMP-9 null (null, n. = 85) mice were divided into 4 groups at 3. h post-MI: saline (S), aliskiren (A; 50. mg/kg/day), valsartan (V; 40. mg/kg/day), or A. +. V and compared to no MI controls at 28. days post-MI. All groups had similar infarct areas, and survival rates were higher in the null mice. The treatments influenced systolic function and hypertrophy index, as well as extracellular matrix (ECM) and inflammatory genes in the remote region, indicating that primary effects were on the viable myocardium. Saline treated WT mice showed increased end systolic and diastolic volumes and hypertrophy index, along with reduced ejection fraction. MMP-9 deletion improved LV function post-MI. Aliskiren attenuated the increase in end systolic volume and hypertrophy index, while valsartan improved end diastolic volumes and aliskiren. +. valsartan improved the hypertrophy index only when MMP-9 was absent. Extracellular matrix and inflammatory gene expression showed distinct patterns among the treatment groups, indicating a divergence in mechanisms of remodeling. This study shows that MMP-9 regulates aliskiren and valsartan effects in mice. These results in mice provide mechanistic insight to help translate these findings to post-MI patients.

KW - Aliskiren

KW - Extracellular matrix

KW - MMP-9

KW - Myocardial infarction

KW - Remodeling

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=84901310496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901310496&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2014.04.007

DO - 10.1016/j.yjmcc.2014.04.007

M3 - Article

VL - 72

SP - 326

EP - 335

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

ER -